These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 25248569

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
    Abifadel M, Guerin M, Benjannet S, Rabès JP, Le Goff W, Julia Z, Hamelin J, Carreau V, Varret M, Bruckert E, Tosolini L, Meilhac O, Couvert P, Bonnefont-Rousselot D, Chapman J, Carrié A, Michel JB, Prat A, Seidah NG, Boileau C.
    Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH, O'Reilly P, Lu C, Gomes J, Lagace TA, Basak A.
    Eur J Med Chem; 2015 Mar 06; 92():890-907. PubMed ID: 25679794
    [Abstract] [Full Text] [Related]

  • 25. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA.
    Circulation; 2012 Nov 13; 126(20):2408-17. PubMed ID: 23129602
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. PCSK9 inhibition: current concepts and lessons from human genetics.
    Rodriguez F, Knowles JW.
    Curr Atheroscler Rep; 2015 Mar 13; 17(3):487. PubMed ID: 25637042
    [Abstract] [Full Text] [Related]

  • 28. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG, Dufour R, Davignon J, Baass A.
    Arterioscler Thromb Vasc Biol; 2014 Dec 13; 34(12):2700-5. PubMed ID: 25278291
    [Abstract] [Full Text] [Related]

  • 29. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB, Holla ØL, Cameron J, Berge KE, Leren TP.
    Clin Chim Acta; 2010 Feb 13; 411(3-4):229-33. PubMed ID: 19917273
    [Abstract] [Full Text] [Related]

  • 30. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L, Robinson JG.
    Prog Cardiovasc Dis; 2015 Feb 13; 58(1):19-31. PubMed ID: 25936907
    [Abstract] [Full Text] [Related]

  • 31. PCSK9 inhibitors.
    Farnier M.
    Curr Opin Lipidol; 2013 Jun 13; 24(3):251-8. PubMed ID: 23652470
    [Abstract] [Full Text] [Related]

  • 32. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G, Petrides F, Chatelais M, Blom DJ, Choque B, Tabet F, Wong G, Rye KA, Hooper AJ, Burnett JR, Barter PJ, Marais AD.
    J Am Coll Cardiol; 2014 Jun 10; 63(22):2365-73. PubMed ID: 24632287
    [Abstract] [Full Text] [Related]

  • 33. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Grenkowitz T, Kassner U, Wühle-Demuth M, Salewsky B, Rosada A, Zemojtel T, Hopfenmüller W, Isermann B, Borucki K, Heigl F, Laufs U, Wagner S, Kleber ME, Binner P, März W, Steinhagen-Thiessen E, Demuth I.
    Atherosclerosis; 2016 Oct 10; 253():88-93. PubMed ID: 27596133
    [Abstract] [Full Text] [Related]

  • 34. PCSK9: an emerging target for treatment of hypercholesterolemia.
    Duff CJ, Hooper NM.
    Expert Opin Ther Targets; 2011 Feb 10; 15(2):157-68. PubMed ID: 21204732
    [Abstract] [Full Text] [Related]

  • 35. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
    Page MM, Stefanutti C, Sniderman A, Watts GF.
    Clin Sci (Lond); 2015 Jul 10; 129(1):63-79. PubMed ID: 25881720
    [Abstract] [Full Text] [Related]

  • 36. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A, Demir K, Altunkeser BB.
    Turk Kardiyol Dern Ars; 2014 Oct 10; 42 Suppl 2():56-67. PubMed ID: 25693363
    [Abstract] [Full Text] [Related]

  • 37. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
    Si-Tayeb K, Idriss S, Champon B, Caillaud A, Pichelin M, Arnaud L, Lemarchand P, Le May C, Zibara K, Cariou B.
    Dis Model Mech; 2016 Jan 10; 9(1):81-90. PubMed ID: 26586530
    [Abstract] [Full Text] [Related]

  • 38. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction.
    Davidson MH.
    J Clin Lipidol; 2013 Jan 10; 7(3 Suppl):S11-5. PubMed ID: 23642323
    [Abstract] [Full Text] [Related]

  • 39. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
    Le QT, Blanchet M, Seidah NG, Labonté P.
    J Biol Chem; 2015 Sep 18; 290(38):23385-400. PubMed ID: 26195630
    [Abstract] [Full Text] [Related]

  • 40. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M.
    J Clin Endocrinol Metab; 2015 Jan 18; 100(1):E41-9. PubMed ID: 25313916
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.